Wiedemann G J, Robins H I, Katschinski D M, Mentzel M, D'Oleire F, Kutz M, Wagner T
Medical University of Lübeck, Germany.
Anticancer Res. 1997 Jul-Aug;17(4B):2899-902.
Preclinical studies are consistent with the concept that 41.8 degrees C whole body hyperthermia (WBH) can enhance the therapeutic index of specific chemotherapeutic agents. These laboratory investigations resulted in 2 phase I clinical studies, which also support this hypothesis. These trials were extended to 2 sequential phase II investigations of WBH plus ifosfamide, carboplatin and etoposide (ICE) for refractory sarcoma patients. The first study (involving 12 patients) using extra-corporeal WBH was prematurely closed to adopt a less toxic WBH technology, i.e., the radiant heat Aquatherm. To date, 12 patients have been accrued to the Aquatherm trial. Projections regarding reduced morbidity were correct. The response rate for ICE/WBH is currently 63%. The review to follow will summarize the results of these trials, as well as the laboratory and clinical data which serve to explicate the dramatic clinical results observed to date.
41.8摄氏度的全身热疗（WBH）可提高特定化疗药物的治疗指数。这些实验室研究促成了两项I期临床研究，它们也支持这一假设。这些试验扩展至两项关于难治性肉瘤患者的全身热疗联合异环磷酰胺、卡铂和依托泊苷（ICE）的连续II期研究。第一项使用体外全身热疗的研究（涉及12名患者）因采用毒性较小的全身热疗技术（即辐射热Aquatherm）而提前结束。迄今为止，已有12名患者参与了Aquatherm试验。关于发病率降低的预测是正确的。ICE/WBH目前的缓解率为63%。接下来的综述将总结这些试验的结果，以及用于解释迄今观察到的显著临床结果的实验室和临床数据。
